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Normal aging brings with it changes in dopaminergic and memory
functions. However, little is known about how these 2 changes are
related. In this study, we identify a link between dopamine,
episodic memory networks, and aging, using pharmacological
functional magnetic resonance imaging. Young and older adults
received a D2-like agonist (Bromocriptine, 1.25 mg), a D2-like
antagonist (Sulpiride, 400 mg), and Placebo, in a double-blind
crossover procedure. We observed group differences, during
memory encoding, in medial temporal, frontal, and striatal regions
and moreover, these regions were differentially sensitive across
groups to dopaminergic perturbation. These ﬁndings suggest that
brain systems underlying memory show age-related changes and
that dopaminergic function may be key in understanding these
changes. That these changes have behavioral consequences was
suggested by the observation that drug modulations were most
pronounced in older subjects with poorer recognition memory. Our
ﬁndings provide direct evidence linking ageing, memory, and
dopaminergic change.
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Introduction
The cognitive decline that accompanies normal aging is
characterized by selectivity as well as generality in the pattern
of changes (Light 1991; Salthouse 1996). The marked
impairment in episodic memory is thought to arise at least in
part from difﬁculty in encoding new memories (Craik and
Rabinowitz 1985; Perfect et al. 1995; Glisky et al. 2001;
Friedman et al. 2007). This pattern of functional change may
be linked to regional cerebral atrophy, notably in prefrontal
cortex (PFC; Raz et al. 1997), and medial temporal lobes
(Golomb et al. 1993; see Raz and Rodrigue 2006).
However, a full understanding of age-related changes
requires a consideration of the accompanying changes in
neurotransmission. There is a substantial age-related decline in
dopamine system markers, especially in striatum—of the order
of 8% per decade. Postmortem and radioligand binding data
have revealed age-related reductions in the number of D1 and
D2 receptors, and dopamine (DA) transporters (for reviews see
Joseph et al. 1990; Li and Lindenberger 1999; Kaasinen and
Rinne 2002; Backman et al. 2006). There is evidence, too, that
these changes have perceptuomotor and cognitive correlates
(Volkow et al. 1998; Wang et al. 1998; Mozley et al. 2001) that
can account for speciﬁc age-related variance in measures of
episodic memory, verbal ﬂuency and perceptual speed (Back-
man et al. 2000; Yang et al. 2003; Erixon-Lindroth et al. 2005).
These ﬁndings are consistent with those from animal studies
which have demonstrated age-related reductions in DA and
dopaminergic markers, and associated functional changes,
notably in PFC, striatum, and medial temporal lobes (MTL)
(Goldman-Rakic and Brown 1981; Lai et al. 1987; Araki et al.
1997; Amenta et al. 2001). Computational models, which can
emulate patterns of memory decline, also link DA deﬁciency to
age-related reductions in signal-to-noise characteristics and
processing efﬁciency (Li et al. 2001; Braver and Barch 2002; Li
et al. 2005).
In the current study, we sought direct evidence that goes
beyond the ‘‘correlative triad’’ observed between adult age, DA,
and cognition in humans (Backman et al. 2006), We used
functional magnetic resonance imaging (fMRI) to measure
speciﬁc brain responses to episodic encoding processes in
young and old subjects. To determine the relationship between
dopaminergic neuromodulation and episodic encoding, we
used blinded pharmacological manipulations in the same sub-
jects, with both a DA agonist (Bromocriptine) and an antagonist
(Sulpiride). We assessed the differential effects of dopaminer-
gic perturbation on encoding-related activity in young and
older adults using ‘‘subsequent memory’’ (SM) measures of the
regional brain activity at the time of encoding predictive of
success on a later memory test (Sandquist et al. 1980; Wagner
et al. 1998). These measures assess the activity elicited by
processes speciﬁcally associated with successful encoding,
independently of other processing engaged during an orienting
task. Such studies in the young have shown that DA plays
a critical role in episodic encoding in humans (Wittmann et al.
2005; Schott et al. 2006). Our aim was to establish a link
between aging and changes in DA transmission, processes
involved in episodic encoding, and the regions and networks
that support these processes.
Our speciﬁc predictions for the 2 groups were as follows.
According to the dopamine aging hypothesis, an amelioration of
processing inefﬁciency of older adults under dopaminergic
stimulation (Bromocriptine) was expected, and thus an attenu-
ation of the differences from the young. Conversely, the anta-
gonist (Sulpiride) was predicted to render patterns of activity in
the young more like those in the old, with evidence of reduced
neural efﬁciency reﬂected in larger SM effects. This was based on
evidence linking optimal levels of DA signaling to optimal neural
efﬁciency, associated with reduced cortical activity alongside
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2000; Gibbs and D’Esposito 2005). Parallel effects on behavior
were predicted, although these were expected to be subtle
given the relatively low drug doses. The use of such modest
doses in pharmacological neuroimaging studies has the impor-
tant advantage of avoiding confounds of task-speciﬁc effects of
drugs with secondary inﬂuences due to altered arousal or other
systemic or general effects (Honey and Bullmore 2004). In this
context, we examined the link between neuromodulation and
behavior in terms of individual differences in cognition. Given
the relationship between aging, dopaminergic markers and
individual differences, we investigated whether drug effects
would vary according to memory performance. We predicted
that drug effects—speciﬁcally of the agonist, Bromocriptine—in
the older group would be more pronounced in those with
poorer memory, that is, those likely to have the greatest
underlying age-related cognitive decline. This speciﬁc prediction
extended the expectation that DA stimulation would ameliorate
group differences via predominant effects in the older group.
Critically, and more generally, an effect of age on the relationship
between performance and dopaminergic neuromodulation in
this task would suggest that the changes in DA systems
associated with aging are a marker, if not an integral part, of
the mechanisms underlying age-related memory decline.
Materials and Methods
Subjects
Sixteen younger (18--35 years) and 16 older (63--79 years) adults
underwent functional MRI scanning. Of these, 15 (mean = 24.9, SD = 4.7
years) and 12 (mean = 66.9, SD = 3.3 years) contributed data to the
present study. There were the following exclusions: a young participant
with too few forgotten items (see fMRI Scanning and Data Analysis), an
older participant with an error in fMRI data acquisition in one session,
and 3 further older subjects who gave no ‘‘Know’’ responses in one or
more sessions (see Behavioral procedures). Recruitment was via locally
placed advertisements, with initial telephone screening of volunteers
using a standard questionnaire. Exclusion criteria were a history of
signiﬁcant medical or psychiatric condition likely to affect the brain or
cerebral vasculature, concurrent vasoactive or neurotropic medication,
and any contraindications to the study drugs or to MRI. Prior to taking
part in functional MRI scanning, each subject had an electrocardiogram,
reviewed by a physician, as well as a structural scan. The 2 groups were
matched as far as possible on education and on ‘‘crystallized’’ IQ, as
estimated by the National Adult Reading Test (NART; Nelson 1982). For
those young and old included in the fMRI analysis, years of formal
education were equivalent (mean 4.5 and 4.4 years after age 16 for
young and old, respectively), but they differed marginally in NART IQ
(mean estimated full scale IQ = 112.0 and 117.3, SDs = 6.2 and 6.9;
t(22.4) = 2.97, 0.05 < P < 0.1). Older volunteers also completed the
Mini Mental State Examination, and a minimum score of 28 was
required for participation (Folstein et al. 1975; Lezak 1995). The study
was approved by the Cambridge Local Research Ethics Committee,
Cambridge, UK.
Pharmacological Interventions
The study employed a randomized double-blind Placebo-controlled
crossover design, each subject attending for 3 main sessions during
which oral study medication was given by a physician. This medication
contained Sulpiride 400 mg, Bromocriptine 1.25 mg, or a Placebo. To
prevent nausea whilst maintaining a double-blind procedure, the study
drug on each visit was given with 10 mg of the peripheral DA
antagonist Domperidone (Reddymasu et al. 2007). Subjects were also
asked to eat before attending. Sulpiride has a mean time to maximal
plasma concentration of about 3 h, a plasma half-life of about 12 h, and
oral bioavailability of around 35%. Plasma prolactin concentration is
maximal after about 1 h, then declines slowly (Wiesel et al. 1982; von
Bahr et al. 1991; Caley and Weber 1995). Bromocriptine’s central
effects have been shown to be somewhat slower in onset than those of
Sulpiride but are also long lasting. Prior data suggest a reliable
suppression of plasma levels from as early as 1½ h postdose, that
does not reach a maximum until after 3 h postdose and persists for
some time after that (Luciana et al. 1998; Muller et al. 1998; Oranje et al.
2004). fMRI data acquisition commenced at approximately 3-h
postdrug. The encoding phase was administered ﬁrst and lasted for
15 min. The ﬁrst of the 2 retrieval phase (fMRI data not reported here)
commenced around 2 min later. This was followed by a 10-min period
of an unrelated task (not reported here), then the second retrieval
phase. Each of these retrieval phases lasted for just over 17 min. Study
visits were separated by a minimum washout period of a week.
Behavioral Procedures
The episodic memory task consisted of a study phase, comprising
stimulus attribute decision tasks, and a test phase, comprising 2
recognition memory blocks. The choice of the 2 study phase tasks was
motivated primarily by the requirement that with the data collapsed
across them there should be sufﬁcient numbers of remembered and
forgotten items in the 2 age groups for the fMRI analysis. On the ﬁrst
visit, immediately after the drugs had been given, subjects received task
training and practice outside the scanner until they were familiar with
the procedure. Instructions for the decision tasks and the memory test
were given together, and subjects were informed that both phases
were equally important. Standard instructions, with examples, were
given for the Remember-Know procedure (Gardiner 1988).
Study Phase
The study phase comprised a series of 16 blocks of 15 trials each, with
interspersed periods of ﬁxation. This design was employed to minimize
the requirement for subjects to switch between encoding tasks whilst
employing an efﬁcient fMRI design. Each block was preceded by a cue,
‘‘Living?’’ or ‘‘Syllables?,’’ to indicate whether subjects should perform
a living/nonliving or a syllable judgment on the items in that block. On
each trial, a noun was presented in the center of the screen. On living/
nonliving judgment trials, subjects decided whether the named item
was a living or a nonliving thing. On syllable judgment trials, they
decided whether the word had an even or an odd number of syllables.
The stimulus onset asynchrony (SOA) at study was 3000 ms: each item
was presented for 600 ms, followed by a ﬁxation ‘‘+’’ for 2200 ms. The
screen was then blanked for 200 ms prior to the next trial.
Test Phase
In the test phase, subjects again saw single words presented in central
screen. For each, they were asked to judge whether, and how, they
remembered that word being presented in the study phase. If they
could remember something speciﬁc about seeing the word at study
(e.g., what they thought about when they saw the word, the key that
was pressed, or what the word looked like on the screen), they were
asked to give a ‘‘remember’’ (R) response. If they had no speciﬁc
recollection of experiencing the item, but thought that the item had
been studied, they were asked to give a ‘‘know’’ (K) response. If they
thought that the item had not been studied, they were asked to give
a ‘‘new’’ response. Each half of the test phase comprised 18 blocks of 10
trials, interspersed with periods of ﬁxation. Each was preceded by
a cue, ‘‘Remember living’’ or ‘‘Remember syllable,’’ which indicated that
any previously seen items in the block that followed would be those
from just 1 of the 2 study phase tasks. The SOA at test was 4400 ms:
each item was preceded for 600 ms by a warning signal, which was
a change in the color of the ﬁxation symbol from white to red. The
word was then shown for 600 ms, followed by a ﬁxation ‘‘+’’ for 3000
ms, and a blank screen for 200 ms.
Stimuli
The lists of critical stimuli were constructed from a pool of 1080 nouns
between 4 and 9 letters, and between 1 and 3 syllables in length from
the CELEX database (http://www.ru.nl/celex/). Three sets of 360
words each were selected at random from this pool, each having the
same proportion of items that were living versus nonliving, items that
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number of letters. For each matched pair of one younger and one older
subject, 18 lists of 60 words each were formed from this pool, 6 for
each study session. Random selection was again constrained to give an
even distribution of encoding task-related characteristics (i.e., number
of syllables and animacy) across lists. Of the 6 lists, 4 were used as
studied items (2 for living/nonliving decisions and 2 for syllable
judgments), and the other 2 were used as new items at test. One of the
2 study lists, and 1 of the 2 new item lists, were combined to create the
list for each of the 2 test blocks for each session. An additional 90 items
formed practice lists for the study and test phases. Except where noted,
data in both behavioral and fMRI analyses are collapsed across the 2
encoding tasks. Word stimuli were presented using DMDX (http://
www.u.arizona.edu/~kforster/dmdx/dmdx.htm), via a mirror comfort-
ably situated within the subject’s ﬁeld of view. Words were displayed in
white uppercase Arial font on a black background. Responses were
made using a hand-held response box with counterbalanced response
mappings across subjects. In both study and test phases, both speed and
accuracy were stressed.
Other Measures
In order to assess nonspeciﬁc drug effects, subjects were required to
complete 2 further tests at the start of each session, just before
scanning commenced, and at the end of the session. The ﬁrst was an
analog Apathy Scale consisting of 5 100-mm lines ranging from ‘‘not at
all’’ to ‘‘very’’ for the following items: motivated, excited, energetic,
interested and full of initiative (McLean et al. 2004). Subjects were
required to indicate a point on each line that was consistent with their
current subjective feeling. The second was a 10-item version of the
Benton judgment of line orientation test (Benton et al. 1983). In the
ﬁnal session, they were also asked to report in which sessions they
thought they had received drugs versus Placebo.
Analysis of Behavioral Data
All analysis of behavioral data were conducted using full-factorial
ANOVA with the principal factors of age group (young, old) and drug
(Sulpiride, Placebo, Bromocriptine). The analysis of study phase mean
response times (RTs), and proportions of correct responses, also
included the factor SM (whether items attracted R or K responses, or
were forgotten, F, i.e., classiﬁed as new). Test phase RT analysis had the
factors of age group, drug, and old/new (hits/correct rejections). In the
test phase, discrimination of old from new items across both R and K
responses was indexed by Pr = (Phit – Pfalse alarm) (Snodgrass and Corwin
1988). The response bias index Br was also computed (Pfalse alarm/1 –
(Phit – Pfalse alarm) (Snodgrass and Corwin 1988): values less than 0.5
suggest a conservative tendency to classify both old and new items as
‘‘new.’’ As ‘‘remembered’’ items deﬁned the SM measures (see fMRI
scanning and data analysis), age group and drug effects on the
proportions of items judgments recollected versus familiar, and on
RTs for these response categories, were also assessed. Separate
ANOVAs were conducted on the level of recollection (using the
corrected R proportions index: proportion of R hits—proportion of R
false alarms (Gardiner and Java 1991), the level of familiarity under the
assumption of independence (Yonelinas and Jacoby 1995), and
comparing the 2 (with the additional factor of recollection vs.
familiarity). The latter analysis was also conducted for RTs.
fMRI Scanning and Data Analysis
Subjects performed the stimulus attribute decision tasks while T2*-
weighted gradient-echo echo planar (EPI) images with blood oxygen
level-dependent contrast were acquired, using a 3.0T Medspec S300
system (Bruker Medical, Ettlingen, Germany) in the Wolfson Brain
Imaging Centre (Cambridge, UK). Each EPI volume consisted of 23
interleaved 4 mm thick a3ial slices with 64 3 64 pixels, separated by
a 1-mm interslice gap, angled to the intercommisural line. Seven
hundred and ﬁfty-ﬁve volumes were acquired, with a ﬂip angle of 90 ,
a repetition time (TR) of 1200 ms, an echo time of 27.5 ms, and an in-
plane resolution of 3.125 mm. The ﬁrst 7 volumes were discarded to
allow for T1 saturation effects.
Preprocessing
Preprocessing and data analysis were carried out using Statistical
Parametric Mapping (SPM5, Wellcome Department of Cognitive
Neurology, London, UK; Friston et al. 1995, http://www.ﬁl.ion.ucl.a-
c.uk/spm/spm5). Data quality control employed outlier detection
(slices of variance >5 standard deviations) to identify problem scans.
Where present, these were replaced with the mean of the 2
neighboring scans to avoid the generation of temporal interpolation
artifacts during slice timing correction. They were then modeled as
confounds in the design matrix by placing a ‘‘1’’ at the appropriate time-
point in a column of zeros (see below). All volumes in each time series
were realigned spatially to the ﬁrst volume, using B-spline interpolation.
Inspection of movement parameters generated during spatial
realignment indicated that no participant moved more than 3 mm or
3  in any direction during task performance. Each volume was
normalized using nonlinear basis functions and then resampled into 3
3 3 x 3 mm voxels, using a standard EPI template volume based on the
Montreal Neurological Institute (MNI) reference brain (Cocosco et al.
1997) in the space of Talairach and Tournoux (1988; Ashburner and
Friston 1999). Finally, to allow for anatomical variation between as well
as within the 2 age groups (Good et al. 2001); see (Morcom et al. 2003),
the time series was smoothed with a 10-mm full width half maximum
isotropic Gaussian kernel.
First Level Models
The fMRI effects reported pertain to the memory encoding phase.
Population inferences were made using a 2-stage ‘‘summary statistic’’
procedure (Holmes and Friston 1998). In the ﬁrst stage, the volumes
acquired for each participant were modeled as a continuous time
series. Trials at study were classiﬁed according to SM performance, that
is, responses in the test phase. There were thus 3 main event types:
studied items that attracted a ‘‘remember’’ decision (R items), those
that attracted a ‘‘know’’ decision (K items), and those that attracted
a ‘‘new’’ decision (forgotten or F items). Those items wrongly classiﬁed
during the study phase were modeled as events of no interest in the
fMRI analysis, as were the 2 types of study task cues preceding each of
the mini-blocks. The hemodynamic response to the onset of each event
type of interest was modeled with 2 basis functions: a canonical
hemodynamic response function (HRF; Friston et al. 1998), and a
delayed HRF (Henson et al. 2000), shifted 2.5 s later in time than the
canonical HRF (see Morcom et al. 2003 for a similar approach). This
approach does not assume that event-related responses ﬁt the
‘‘canonical’’ shape. We also employed ‘‘early’’ and ‘‘late’’ response fun-
ctions speciﬁcally because aging may affect the shape and/or timing of
the hemodynamic response as a result of cerebrovascular changes
([although we note that studies to date have not revealed consistent
such effects (D’Esposito et al. 1999; Huettel et al. 2001; Aizenstein et al.
2004; Ances et al. 2009]). Thus, event-related responses with a different
shape or timing in the 2 age groups could be detected and
distinguished from event-related responses of different magnitudes.
Sequences of delta functions representing the onsets of events for
each trial type were convolved with the early and the late response
functions to form the covariates in a general linear model, together
with a constant term for each participant. The covariates for the late
HRF were orthogonalized with respect to those for the early HRF using
a Gram-Schmidt procedure, giving priority to the early covariate
(Andrade et al. 1999). Variance common to the early and late covariates
was thus attributed to the early covariate, so that loadings on the
orthogonalized late covariate accounted only for residual variance in
the data unexplained by the early covariate. This avoided variance being
‘‘lost’’ due to collinearity and meant that early covariate effects were
interpretable as canonical event-related responses. Parameter estimates
for each covariate were calculated from the weighted least squares ﬁt
of the model to the data, following prewhitening based on an AR(1)
plus white noise model to remove autocorrelations in the time series
(Friston et al. 2002). The data for each session were proportionally
scaled to a global mean of 100. Using a discrete cosine basis set ﬁtted as
part of the model, the data were high-pass ﬁltered to a maximum of 1/
128 Hz. Twelve covariates were also included for each session to
capture residual movement-related artifacts (the 3 rigid body trans-
lations and rotations determined from the realignment stage, and their
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estimates were then computed for the combinations of conditions
speciﬁed in the Results section, for both early and late covariates. These
contrast images were stored separately for each participant, and
entered into second level or ‘‘random effects’’ models, which permit
inferences about condition effects across subjects and between groups
that generalize to the population.
Second Level Models and Analysis Strategy
Group level models and covariates. The group level analyses focused
on drug modulations of activity at encoding predicting SM, and on age-
related differences and commonalities in these drug modulations. An
ANCOVA model was constructed with the categorical factors of group
(young, old) and drug (Sulpiride, Placebo, Bromocriptine). Because the
relationship between brain activity and individual memory perfor-
mance was of interest, Pr measures were also entered into the second
level designs as predictors using 6 covariates (see Introduction for
rationale, and Results and Discussion: Behavioral ﬁndings for details of
measures). Covariates for each drug condition across age groups were
constructed in 3 columns. Covariates for age group 3 Pr were con-
structed by mean correcting score vectors for young and older subjects
separately, weighting the young group values positively and the older
group values negatively, and then combining them in a single column
for each drug condition. To account for possible confounding effects of
Br, these measures were entered into the models in the same fashion,
but were not analyzed further. In order to interpret the drug effects in
terms of baseline age-related differences, analyses were ﬁrst conducted
for the Placebo condition alone.
All of these second level analyses were conducted using ﬁrst level SM
contrast images as dependent measures. These were formed from the
difference between the estimated activity at each voxel for items later
judged ‘‘remembered’’ and those forgotten (R – F). In this way, the
activity speciﬁcally associated with encoding leading to later recollec-
tion in both groups was contrasted with that associated with
unsuccessful encoding. The contrasts were deﬁned in this way so that
between-groups comparisons of SM effects would not be confounded
with differing levels of recollection for remembered items, recollection
being expected to be lower in the old group (Yonelinas 2001).
However, the use of R, not K, items to form SM effects was not intended
to isolate encoding leading to later recollection from that leading to
later familiarity, because, depending on the processing model, at least
some recollected items are likely also to be familiar (see Yonelinas and
Jacoby 1995). Effects elicited by items later judged ‘‘known’’ are not
reported because K responses are likely to reﬂect a mixture of
familiarity and guessing, the rate of the latter varying according to
response criterion (which here showed drug effects, see Results;
Yonelinas et al. 1996). SM-related activity was not assessed separately
for the 2 different study (stimulus attribute decision) tasks because
there were not enough trials to do this reliably given the variability in
memory performance (see online Supplementary Material for analysis
of effects under Placebo). All models were estimated using a weighted
least squares procedure that accounted for nonsphericity. Contrasts of
second level parameter estimates produced SPMs of F or t statistics at
each voxel, subsequently transformed to the unit normal Z distribution.
Thresholding strategy and region identiﬁcation. To minimize the
number of statistical tests at each voxel, effects were in general
detected using (nondirectional) F-tests, then further delineated using
speciﬁc 1- and 2-sample t-tests where appropriate. To control the false
positive rate across voxels, a region of interest (ROI) mask was deﬁned
combining regions from the AAL template using WFU PickAtlas
(Tzourio-Mazoyer et al. 2002; Maldjian et al. 2003). This comprised
bilateral medial temporal lobes (hippocampus and parahippocampal
gyrus), bilateral lateral PFC (inferior and middle frontal gyri but not
orbitofrontal cortex), and bilateral striatum (caudate, putamen and
lentiform nucleus). Also included was the region deﬁned by Aron et al.
(2004) to include the ventral tegmental area (a 15-mm sphere centered
on x = 0, y = –15, z = –9). These ROIs were chosen because the MTL and
thelateralPFCaretheregionsofprimaryinterestinthestudyofepisodic
memory, and speciﬁcally in the study of episodic memory and ageing
(see Introduction). The striatum is commonly assumed to be involved in
procedural, rather than episodic, memory, but is both a central part of
the DA system and the region in which an age-related decline is
dopaminergic markers has most clearly been demonstrated in humans
(see Introduction). The dopaminergic midbrain is also of potential
functional relevance particularly in the light of recent ﬁndings of Schott
et al. (2006). An uncorrected threshold of P < 0.001, and > 5 contiguous
voxels was adopted across this search volume of 8855 voxels (using
a Bonferroni correction at alpha = 0.05, 9 false positive voxels would be
expected—however, given the smoothness of the data, there are fewer
observations than voxels, so this is a conservative estimate; see Nichols
and Hayasaka (2003). Second level contrasts were evaluated at all voxels
within the ROIs. The locations of maxima of suprathreshold regions
were established by rendering them onto the volunteers’ normalized
structural and mean EPI images, and the MNI reference brain (Cocosco
et al. 1997). They were labeled using the nomenclature of Talairach and
Tournoux (1988) and anatomical designations of Brodmann (1909).
Results from the late covariate are not reported here because in no case
did they add meaningfully to the ﬁndings from the early covariate; they
are available from the ﬁrst author on request.
Effect combination and masking strategy. In the case of all but the
highest level interaction, exclusive masking was employed to discount
any voxels where there were higher order effects, thresholded at P <
0.05 uncorrected (e.g., age group and drug effects were exclusively
masked with interactions of age group 3 drug and interactions
involving drug 3 Pr). To assess effects common to both age groups,
however, a strict criterion was adopted that the effect should be
reliable in both groups at P < 0.001, uncorrected. This was
implemented by inclusively masking t-statistic maps from the young
with those from the old. When reporting masked contrasts, the Z values




The stimulus attribute decision tasks were performed with an
average accuracy of 90% and 89% (SDs = 7% and 8%) by young
and older subjects, respectively. There were no reliable effects
of age group or drug on the proportion of correct responses,
and no effect of these factors nor of SM on response times (RTs;
means in young and old = 1130 and 1148 ms, SDs = 276 and 148
ms; performance at study also did not differ between the 2
study tasks: see online Supplementary Material).
Test Phase
Old/new item discrimination. Memory test performance is
summarized in Figure 1 and the indices used are described in the
Materials and Methods. There was a reliable main effect of drug
on the ability to discriminate old from new items (F2.0,48.8 = 4.20,
P < 0.05), item recognition increasing with increasing D2-like
stimulation across both groups. However, neither drug effect
was individually signiﬁcant against Placebo (for Sulpiride versus
Placebo, t(26) = 1.79, 0.05 < P < 0.1; for Bromocriptine versus
Placebo, t(26) < 1). Also, although the drug 3 age group
interaction was not signiﬁcant (F2.0,48.8 = 1.49), the main effect of
drug was only reliable in the old when the groups were
considered separately. Given the imaging results, further analyses
also tested for drug effects on memory discrimination that varied
according to individual baseline discrimination performance:
a correlation of the discrimination index Pr on Placebo with the
linear increase in Pr across drug conditions yielded no signiﬁcant
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Analyses of response bias, test phase RTs, and differences
between the 2 study tasks on Pr are given in the online
Supplementary Material: none of these showed any evidence of
memory-speciﬁc drug effects (see also Supplementary Table S1).
Recollection and familiarity. There were no reliable effects of
age group or drug on the level and relative proportions of
memory based upon recollection and familiarity, although
recollection was somewhat lower in the older group (mean
corrected R proportion = 0.36/SE 0.03 and 0.28/0.04 for young
and old; see online Supplementary Table S1 for full details).
However, on Sulpiride, subjects were more likely to classify
items as ‘‘known’’ regardless of whether they were old or new, in
keeping with Sulpiride’s effect on response criterion (for main
effect of drug, F1.6,38.9 = 3.95, P < 0.05; see Table S1). The ori-
enting task used at study also affected the level of recollection,
as for overall recognition, but here there was only a trend to
a group difference, which reﬂected a tendency for group
differences in the probability of later recollection to be greater
for the deep than for the shallow task (for main effect of deep vs.
shallow, F1,25 = 204.66, P < 0.001; for interaction, F1,25 = 3.23,
0.05 < P < 0.1; mean R discrimination = 0.43 for deep study task,
and 0.21 for shallow (for young 0.48 deep/SE 0.03 and 0.23/0.04
for shallow; for old 0.38/0.04 and 0.19/0.04]).
Other Measures
Subjects’ subjective reports suggested that they could not
consciously determine when they had received a drug. The
Apathy analog rating scales and the Judgment of Line Orientation
tests also did not reveal any reliable effects of the drugs (see
online Supplementary Material).
fMRI Findings
We compared activity elicited by subsequently recollected (R)
items with that elicited by subsequently forgotten (F) items,
that is, those later afforded ‘‘remember’’ versus ‘‘new’’ judg-
ments. This comparison (later remembered vs. later forgotten)
will be referred to as SM-related activity. The analysis strategy is
described in full in Materials and Methods: fMRI scanning and
data analysis. In brief, we ﬁrst examined drug-free effects in the
2 age groups, under Placebo, and then went on to characterize
the drug effects and the effects across the 3 drug conditions.
These analyses were conducted using an ANCOVA model of
SM-related activity. Under Placebo, we analyzed baseline age-
related differences (main effect of age group) and commonal-
ities (overlapping effects in young and old) in SM-related
activity. We tested for the following effects across the 3 drug
conditions: drug modulations that differed according to age
(age group 3 drug interactions), commonalities between the
groups in drug modulations of SM-related activity (overlapping
drug main effects in young and old), group differences in SM-
related activity across drug conditions (main effect of group),
and activity common to both age groups (overlapping effects in
young and old across drug conditions). Importantly, higher
order group differences and commonalities involving the
additional factor of Pr were also assessed in both sets of
analyses. We describe the higher order effects ﬁrst. For clarity
with respect to the direction of SM-related activity, the ﬁndings
are reported in terms of SM effects—greater activity associated
with items later recollected than forgotten (R > F)—and
subsequent forgetting effects—greater activity for items later
forgotten than recollected (R < F). All analyses were performed
within all regions of interest within medial temporal lobes,
lateral PFC, striatum and midbrain (no reliable effects were
seen in the midbrain ROI at the threshold set).
Analyses of the Placebo Condition
Group differences in Placebo condition effects. There were
group differences in activity predicting SM in left posterior
MTL, in anterior left inferior and middle frontal gyri, and in
bilateral dorsal striatum (see Table 1 and Fig. 2). In general,
these were crossover interactions, with SM effects in the young
and subsequent forgetting effects in the old. Follow-up tests of
simple effects indicated that the effects in the young were the
more robust in most regions (see Table 1). In MTL, however,
subsequent forgetting effects in the old were prominent.
Interactions of group 3 Pr on Placebo were not signiﬁcant.
Effects common to both age groups. No ROI showed either SM
or subsequent forgetting effects common to both age groups.
In addition, no ROI showed a reliable effect of Pr on SM-related
activity that was common to both groups.
Follow-up analyses were done in the groups separately to
clarify the pattern of ﬁndings, The forgoing section and Table 1
detail the main regions in which there were SM effects in the
young and subsequent forgetting effects in the old, of those
showing age group 3 SM interactions. It is also of interest that
although the age group 3 SM interaction in left middle frontal
gyrus (at y = 21) appeared mainly driven by SM effects in the
Figure 1. Plots of behavioral data showing mean discrimination of old from new items (indexed by Pr) and mean response bias (indexed by Br) according to age group and drug
condition. For details of measures, see Materials and Methods: Behavioral procedures. Error bars represent the standard errors of the mean.
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Group differences in SM-related activity on Placebo. Regions showing a main effect of age group are shown (contiguous clusters of $5 voxels at P \ 0.001, uncorrected)
Location (x, y, z) Peak Z (n) Region Brodmann area R [ F signiﬁcant
in young group
R \ F signiﬁcant
in old group
15, 6, 24 4.16 (18) Left body of caudate — P \ 0.001 (P \ 0.005)
18, 27, 0 3.50 (11) Right head of caudate — P \ 0.001 (P \ 0.005)
33, 6, 27 3.38 (7) Left precentral gyrus BA 6 P \ 0.001 —
30, 42, 6 3.33 (6) Left posterior parahippocampal gyrus/hippocampus BA 19/37/— (P \ 0.005) P \ 0.001
39, 21, 24 3.25 (6) Left middle frontal gyrus BA 46 P \ 0.001 —
36, 33, 12 3.12 (6) Left inferior frontal gyrus BA 47 (P \ 0.005) —
Note: N refers to the number of signiﬁcant voxels in each cluster; Z refers the Z statistic value for each peak or subpeak; and x, y, and z refer to distances in millimeter from the origin in MNI space (see
Materials and Methods). Follow-up tests assessed SM (R[F) and subsequent forgetting (R\F) effects in the 2 groups; only those that yielded signiﬁcant results are shown. For these, ﬁndings from
comparisons using more lenient thresholds are also shown in brackets to indicate trends. **Indicates reliable at P \ 0.001; *indicates reliable at P \ 0.005
Figure 2. Cross-section images of group main effects under Placebo (green) and group 3 drug 3 Pr effects (red), with parameter estimate (R--F) plots, showing key regions in
which both effects are present. The cross-sections shows signiﬁcant clusters (at P \ 0.001, uncorrected, cluster size $5), superimposed on the SPM5 canonical T1 image
(http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm5/). The plots shows the mean differences in the parameter estimates for the early covariate between remembered (R) and
forgotten (F) items, across subjects for each age group and drug condition, at the peak voxel of the cluster indicated by the relevant white arrow. Error bars represent the
standard error of this difference.
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a region only just anterior to this (32 voxels, peak Z = 3.64; x =
–27, y = 36, z = 18). Most notably, in the reverse contrasts, the
older group did not show any reliable activity positively
predicting SM in the ROIs at the threshold set. In the young,
a single area in right inferior frontal gyrus manifested sub-
sequent forgetting effects (20 voxels, peak Z = 3.98; x = 48, y =
42, z = –3). This overlapped with the interaction of age group 3
drug (see below).
Analyses of Drug Effects
Group and individual differences in drug effects. The most
striking drug modulations of SM effects within the ROIs not
only differed between age groups, but also varied according to
individuals’ level of recognition memory, as indexed by Pr.
These interactions of age group 3 drug 3 Pr for SM measures
were elicited in left posterior MTL, left inferior frontal gyrus,
left anterior PFC, bilateral posterior lateral frontal cortex and
bilateral dorsal striatum, and are summarized in Table 2 and
Figure 2. In the older group, the baseline subsequent forgetting
effects seen on Placebo became more pronounced on
Bromocriptine in the poorer performers. In the young, if
anything, poorer individual performance tended to be associ-
ated with more pronounced SM effects in frontostriatal regions.
As on Placebo, the young consistently showed SM rather than
subsequent forgetting effects in these regions. Follow-up tests
indicated that Bromocriptine was the main determinant of the
group differences; however, the overall picture suggests a
contribution of both agonist and antagonist (see Table 2).
There were differential linear trends in the 2 age groups in the
drug effects on the association between SM measures and
memory performance (linear drug 3 Pr interactions). Positive
linear trends in the older group indicated that D2 stimulation
increased the negative association between memory discrim-
ination performance and the magnitude of subsequent forget-
ting effects. In the young, drug 3 Pr effects were not reliable at
the threshold set, although there were negative linear trends
(see Table 2). The predominance of agonist effects in the old
and antagonist effects in the young may reﬂect a lower baseline
level of DA stimulation in the older group, consistent with
‘‘inverted U’’ models of dopamine function (see Williams and
Castner 2006).
The most striking interaction of age group 3 drug 3 Pr was in
left posterior MTL. This cluster also overlapped that showing the
group 3 SM interaction under Placebo. However, inspection of
the data supporting this correlation between behavior and SM-
related activity suggested that it could have been inﬂuenced by 2
outlier older subjects (see Fig. 3). One had a low Pr due to a high
rate of ‘‘Know’’ false alarms, and another a particularly marked
drug effect (using an outlier criterion of 2 standard deviations
from the mean). Using this conservative procedure, re-analysis of
the data (N = 15, 10) still gave rise to a reliable drug 3 group 3 Pr
interaction in the posterior L MTL region (19 voxels, peak Z =
4.26; x = –27, y = –42, z = –6), with an additional voxel in the
posterior right PFC region (x = 30, y = 6, z = 30). Analyses of
a subset of subjects with the order of drug administration
exactly matched between age groups are also given in the
Supplementary Material.
Average group differences in drug effects. The contrast of the
interaction of age group 3 drug revealed a single region in right
inferior prefrontal gyrus (RIFG; 16 voxels, peak Z = 3.77, x = 39,
y = 27, z = 6). Effects in this region are illustrated in Figure 4,
which suggests a reversal by S of a baseline pattern of crossover
group differences: on P, the young showed SM effects and the
old subsequent forgetting effects (see ANCOVA under P, below
for similar effects in other regions). Follow-up analyses
comparing each drug condition with P conﬁrmed a drug 3
group interaction for S versus P within this regions, but none
for P versus B. Tests in the different drug conditions separately
also showed a group 3 SM interaction on S which overlapped
the group 3 drug effect. Unlike on Placebo, SM-related activity in
the old on S took the form of a SM, as opposed to a subsequent
forgetting, effect (the effect in the young was not signiﬁcant).
The simple effect of S versus P was not reliable in the old group
separately, but was present in the young at a more lenient
threshold (P < 0.005, uncorrected).
Drug effects common to both age groups. There were no
signiﬁcant drug effects common to both age groups.
Discussion
We sought to identify process- and region-speciﬁc changes in
brain responses to episodic encoding in healthy ageing, and
Table 2
Group and individual differences in drug modulations of SM-related activity
Location
(x, y, z)





signiﬁcant in young group
Follow-up contrasts
signiﬁcant in old group
30, 39, 9 4.39 (26) Left posterior parahippocampal gyrus/hippocampus BA 37/19/— O [ Y lin — Overall, Pos lin
33, 6, 27 4.31 (31) Right precentral/inferior frontal gyrus BA 6/44 O [ Y lin, B vs. P (Neg lin at 0.005) Overall, B vs. P
12, 9, 15 4.21 (33) Right caudate body — O [ Y lin, B vs. P (Neg lin at 0.005) Overall, Pos lin, B vs. P
15, 15, 9 4.11 (71) Left caudate body — O [ Y lin, B vs. P — Overall, Pos lin, B vs. P
15, 21, 3 3.75 (17) Right caudate head — O [ Y lin (Neg lin at 0.005) Overall, Pos lin
33, 24, 6 3.70 (13) Left inferior frontal gyrus (anterior) BA 47 O [ Y lin, B vs. P — Overall, Pos lin
42, 3, 27 3.60 (19) Left inferior frontal gyrus BA 9 O [ Y lin, B vs. P — B vs. P
33, 42, 12 3.29 (5) Right anterior middle frontal gyrus BA 10 B vs. P (B vs. P at 0.01) (B vs. P at 0.01)
Note: Regions showing an interaction of age group 3 drug 3 Pr are shown (contiguous clusters of $5 voxels at P\0.001, uncorrected, see Methods). N refers to the number of signiﬁcant voxels in
each cluster; Z refers the Z statistic value for each peak or subpeak; and x, y, and z refer to distances in millimeter from the origin in MNI space (see Materials and Methods). The results of follow-up
contrasts are also shown. These tested interactions of drug 3 Pr in the 2 groups together for each drug versus Placebo separately, that is, Sulpiride versus Placebo, and Bromocriptine versus Placebo (S
vs. P and B vs. P). Further tests assessed positive and negative linear forms of this contrast in the groups separately, and group differences in these effects: Pos lin and Neg lin indicate weightings of the
Pr covariate with [1 0 1] and [1 0 1] respectively across the Sulpiride, Placebo, and Bromocriptine conditions, and O[Y indicates a linear effect that is more positive in the old than in the young (see
text in Results section and Materials and Methods). For the follow-up tests, ﬁndings from comparisons using more lenient thresholds are shown in brackets to indicate trends.
Cerebral Cortex March 2010, V 20 N 3 749Figure 3. Plots of parameter estimates (R--F) against memory performance (Pr) in regions showing an interaction of age group 3 drug 3 Pr. Point plots with ﬁtted regression lines
illustrate activity--performance relationships for peak voxels in MTL, left inferior PFC, and striatum. The x-axis shows Pr for each subject and drug condition; the y-axis shows the
differences in the parameter estimates for the early covariate between remembered (R) and forgotten (F) items. The point plots were generated from individual values extracted from
the peak voxels for each subject, and adjusted for confounding effects of Br using the regress function in MATLAB 6.5 (http://www.mathworks.com/), and plotted against Pr. The best
ﬁt lines to indicate the linear effects of drug at each voxel were computed separately, also using the regress function, and are plotted on the same axes.
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age-related changes. We made a number of important obser-
vations. Key regions—medial temporal lobes, striatum, and
PFC—showed age- and drug-related effects on brain responses
to episodic encoding. In the old, unlike in the young, activity in
these regions was not associated with subsequent successful
remembering. Dopaminergic drug effects differed across
groups in a network of regions including MTL, and these
group differences varied according to individual performance
differences among older subjects. In these regions, Bromocrip-
tine accentuated subsequent forgetting effects in older
subjects, having the greatest impact in individuals with the
poorest recognition memory. Sulpiride, on the other hand, was
associated with an attenuation of subsequent forgetting effects.
In younger subjects, Bromocriptine accentuated SM effects and
Sulpiride attenuated or reversed them, notably in right PFC.
The ﬁndings demonstrate age-related changes in the neural
underpinnings of encoding. They further show that the system
is differentially sensitive to dopaminergic perturbation in old
and young subjects. The accentuation by Bromocriptine of age-
related differences in SM effects does not support our speciﬁc
predictions regarding neural inefﬁciency. However, critically,
many of these effects are correlated with underlying memory
performance: older individuals with the lowest levels of
performance show the most pronounced drug effects. This is
in keeping with our predictions. Below, we consider these
ﬁndings in more detail, focusing on medial temporal and
frontostriatal patterns of activity.
Drug Effects in Medial Temporal Lobes
In the young, words later remembered elicited greater activity
in MTL than those later forgotten. SM effects are thought to
reﬂect processing that directly or indirectly promotes memory
formation (Rugg et al. 2002). The reverse was seen in the old.
The fact that our earlier study and some others have shown
age-invariant SM effects within MTL suggests that these age-
related differences may be modulated by factors such as
encoding task, and we consider this further below (Morcom
et al. 2003; Gutchess et al. 2005; Dennis et al. 2007b). But why
might activity become detrimental to performance? Theoretical
accounts of hippocampal function emphasize the importance
of pattern separation mechanisms for memory trace encoding
(Marr 1982; O’Reilly and McClelland 1994; Treves and Rolls
1994). Thus, MTL-mediated processes may endow memory
traces with a uniqueness that facilitates subsequent recall. If
such processes are suboptimal in the old, undifferentiated
memory traces could be formed, with retrieval failure due to
representational overlap and a paradoxical detrimental effect of
MTL involvement at the encoding stage (Wagner and Davachi
2001). According to Gluck and Myers (1993), MTL may
contribute to dual and opposing effects: ‘‘redundancy com-
pression,’’ which inhibits stimulus-speciﬁc memory, and ‘‘pre-
dictive differentiation,’’ which promotes such memory. This
might explain why activity in the same region appeared
beneﬁcial in one group but detrimental in the other. The
enhancement by Bromocriptine of subsequent forgetting ef-
fects, in poorer performing older subjects, suggests that D2
stimulation potentiated this detrimental tendency. In keeping
with this view, aging animals are thought to fail ‘‘...to encode
new contexts with sufﬁcient distinction from already stored
memories’’ (Wilson et al. 2006). Sulpiride, on the other hand,
seems to dissociate MTL activity from subsequent behavioral
sequelae in both groups. A reduction in the distinctiveness of
neural representations has also been reproduced in network
models which perform similarly to older adults on associative
memory tests. These simulate a deﬁciency in neuromodulation
and reduction in neural signal-to-noise (Servan-Schreiber et al.
1990; Li et al. 2005); see also (Abrams and Taylor 1987; Rypma
and D’Esposito 2000; Li et al. 2001).
The drug effects within MTL may reﬂect dopaminergic
inhibition of the direct cortical pathway to CA1 (Otmakhova
and Lisman 1998) and effects on signaling in entorhinal cortex
(Pralong and Jones 1993; Caruana et al. 2006). The direction of
these effects may be sensitive to the level of stimulation as well
as to pre- and postsynaptic factors (Caruana et al. 2006). This
pathway is thought to regulate the gating of sensory input to
the hippocampus, and to interact with novelty detection
mechanisms, and so may impact on the effectiveness with
which sensory information is incorporated into a new memory
trace (Lisman and Otmakhova 2001).
Drug Effects in Striatum and PFC
The interactions of drug with age group and SM in PFC and
striatum were similar in form to those observed in MTL.
Bromocriptine tended to enhance SM effects in the young, and
subsequent forgetting effects in the poorer performing older
subjects. Thus, as in MTL, increasing D2 stimulation increased
the coupling between activity and subsequent behavior in
a way that depended on individual differences amongst the
older subjects. The pattern of baseline age differences also
Figure 4. Cross-section image of age group 3 drug interaction in right PFC, with parameter estimate (R--F) plot. For details of sections and plots, see legend to Figure 2.
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than subsequent forgetting effects in the old, were prominent.
left inferior frontal gyrus (LIFG) is known to be critical for
encoding in young adults (Wagner et al. 1999). However,
previous studies comparing SM effects in LIFG across age
groups have not shown the differences observed here
(Morcom et al. 2003; Gutchess et al. 2005; Dennis et al.
2007b). These baseline age-related differences are considered
further below. SM effects within striatum are not commonly
examined, but PFC and striatum form parts of a circuit (Voorn
et al. 2004; Leh et al. 2007) known to support episodic
encoding via top-down inputs to MTL (Wagner et al. 1999;
Fernandez and Tendolkar 2001; Addis and McAndrews 2006;
Summerﬁeld et al. 2006; Kopell and Greenberg 2008). Thus the
parallel pattern of ﬁndings in striatum and PFC is perhaps not
surprising. A parsimonious interpretation of the effects of
dopamine manipulation on MTL is therefore that it is secondary
to direct actions on frontostriatal circuitry, most likely via
striatal D2-like receptors (see also Goto and Grace 2008).
Consistent with this, imaging of working memory in the young
have shown D2-like drug effects in striatum (see Mehta et al.
2003). Computational models and animal studies implicate
striatal DA in the maintenance of a balance between updating
working memory representations and stabilizing them against
noise (Crofts et al. 2001; Frank et al. 2001; Gruber et al. 2006;
Hazy et al. 2006). A somewhat speculative possibility is that by
modifying representational stability, DA may also inﬂuence
whether activity in frontostriatal circuits supports or hinders
the formation of long-term memory traces. This may be
analogous to, or contribute to, undifferentiated memory trace
formation in MTL (see above). Recent evidence suggests that
these drugs’ actions in striatum may be primarily presynaptic
(Frank et al. 2006; Mehta et al. 2008), but the locus of the
difference between age groups is not necessarily the same and
presumably relates to the interaction of the drugs with baseline
differences in signaling. An alternative possibility is that fron-
tostriatal drug effects were secondary to actions within MTL
that reduced the efﬁcacy of top-down inputs, giving rise to
parallel drug effects ‘‘upstream.’’ This could also, as noted,
account for the baseline subsequent forgetting effects in the
old seen in MTL.
The interaction of drug with age group in right inferior frontal
gyrus (RIFG) was different in that it was predominantly an effect
of Sulpiride and driven mainly by drug effects in the young. In
contrast to the LIFG, the RIFG is thought to be important in
nonverbal aspects of encoding (Brewer et al. 1998; Golby et al.
2001). Thus, reduced D2 signaling in the young apparently
interfered with this region’s contribution to encoding. This is in
keeping with the tendency of D2-blockade in other regions to
reduce their apparent impact on later remembering.
Baseline Age-Related Differences
The baseline group differences in SM and forgetting effects
differed in key respects from expectation based on earlier data.
These differences are themselves of potential interest in
understanding age-related memory decline. The majority of
prior studies have reported age-invariant SM effects in LIFG
(Morcom et al. 2003; Gutchess et al. 2005; Dennis et al. 2007a;
Miller et al. 2008; Stevens et al. 2008; Duverne et al. 2009).
However a reduction in SM effects in this region in older adults
encoding faces has been observed by Dennis et al. (2008) (see
also Logan et al. 2002). Findings within the MTL have been less
consistent, with age-invariance in some studies (Morcom et al.
2003; Miller et al. 2008; Stevens et al. 2008; Duverne et al.
2009), but larger SM effects in the young in others (Gutchess
et al. 2005; Dennis et al. 2007b, 2008). Only one earlier study
showed MTL subsequent forgetting (R < F) effects speciﬁc to
an older group; that of Gutchess et al. (2005). Their Figure 4
indicates that, as here, an interaction of group 3 SM reﬂected
SM effects in the young, and subsequent forgetting effects in
the old, in bilateral regions slightly posterior and medial to the
L sided cluster reported here (x = ±21 to 24; y = –48 to –51). In
3 separate studies, Dennis et al. (2007a,b, 2008) have also
reported an age-related reduction in SM effects in similar L-
sided posterior MTL regions (negative SM effects were not
analyzed, thus could have been present).
A possible contribution to this cross-study variability within
MTL, and to the present baseline group differences, is the use
of shallow (nonsemantic) as opposed to deep (semantic) study
tasks. An exploratory analysis (see online Supplementary
Material) of SM effects by orienting task suggested that SM
effects were positive in both age groups for the living/nonliving
task in both MTL and LIFG, and reversed in MTL only for the
syllable (shallow) task. The stimuli and procedure used by
Gutchess et al. (2005) differed from ours in several respects but
this study, unlike most earlier ones, employed a shallow visual
orienting task (with stimuli being scenes) at study. Dennis et al.
(2008) also used N-back matching of faces, and found group
differences in LIFG; noted above. This supports the possibility
that the age-related differences in the effectiveness with which
MTL, and perhaps LIFG, mechanisms were engaged reﬂected
the nonsemantic orienting task. As already noted, active but
ineffective processing at the time of encoding may engender
subsequent forgetting effects. We assume, in keeping with the
depth of processing principle (Craik and Lockhart 1972) that
elaborative, meaningful processing in general is more likely to
lead to effective pattern separation and therefore retrievable
memory traces. It has been suggested that such processing is
less likely spontaneously to be engaged with aging (Craik 1983;
Logan et al. 2002; Naveh-Benjamin et al. 2005). However ano-
ther possibility is that with a reduction in the efﬁciency of MTL
pattern separation, a greater speciﬁcity of meaningful process-
ing is required in older adults to achieve the same level of
encoding as the young. We therefore hypothesize that in
a shallow study task, where meaningful links between items
and context are weak and incidental, processing items in the
orienting task may become detrimental to episodic encoding.
Clearly, further data are required to resolve this issue but this
hypothesis offers a possible explanation for the baseline
ﬁndings that is also consistent with the drug effects we report.
Drug Effects on Other Processes
So far, we have considered only drug actions on episodic
encoding. However, drug effects on other aspects of processing
engaged during the orienting task, but not speciﬁcally involved
with encoding, could have impacted the SM modulations we
observed.
Another aspect of the encoding task procedure that differed
from previous studies (e.g., Morcom et al. 2003) was the use of
separate runs of trials for 2 different study tasks. Irrespective of
whether the subsequent forgetting effects in the older group
were truly shallow task-speciﬁc, it is possible that the groups
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of trials, and that there was differential modulation of these
effects according to age and drug. Two prior studies in young
adults have shown state-related encoding effects in LIPFC that
differ in kind or direction from item-related effects (Otten et al.
2002; Reynolds et al. 2004). In a study using semantic encoding
of words, Dennis et al. (2007b) examined sustained as well as
item-related activity that predicted SM, and found that this was
reduced in older adults in posterior and dorsolateral PFC relative
to the young. Such a group difference might have contributed to
the under-recruitment of PFC here (and in other studies that
employed only a single encoding task); however, it was not seen
in LIFG nor in MTL, and subsequent forgetting effects were not
assessed. Further investigations comparing task-set related
effects across age groups are therefore needed to resolve this
issue.
It is also possible that the encoding-related effects were
secondary to drug effects at the time of retrieval. If recollection
were impaired by a drug, only the most strongly encoded items
might later be ‘‘Remembered.’’ If so, the differential activity
between these and forgotten items—SM effects—could be
enhanced. It is possible that, in addition to or instead of acting
on encoding, Bromocriptine impaired later recollection, and
Sulpiride tended to enhance it, in both age groups. Given the
direction of the drug effects on memory performance, this is
less likely than an effect on encoding. However, further studies
employing memory stage-speciﬁc pharmacological interven-
tions are required in order to conﬁrm this. Effects on either or
both stages of episodic memory are of substantial interest in
furthering understanding of age-related memory decline.
Drug Effects on Brain and Behavior
The importance of the drug effect on old/new item discrim-
ination across both age groups is difﬁcult to assess, and
appeared to be driven mainly by an effect in the older group.
This ﬁnding differs from that in a group of comparable age in
a pilot behavioral study (unpublished data).
There have been other recent ﬁndings of variable dopami-
nergic drug effects on performance in long-term memory (as
well as other) tasks in humans. In young adults, sustained
administration of a D1/D2-like agonist (pergolide) has been
shown to impair associative learning (Breitenstein et al. 2006),
whilst in another, levodopa (L-dopa) improved new word
learning (Knecht et al. 2004), and in a third, bromocriptine
improved spatial delayed learning (Mehta et al. 2001); see also
(Mehta et al. 2005, 2008; Mehta and Riedel 2006). In older
animals and adults, DA agonist effects can be similar to those in
the young, but are sometimes attenuated, consistent with
a relative insensitivity to postsynaptic effects (Arnsten et al.
1994, 1995; Cai and Arnsten 1997; Turner et al. 2003; Peretti
et al. 2004). Clearly, future work is needed on the reasons for
this variability: however, the present ﬁndings, as well as work
on genetic polymorphisms such as catechol-O-methyltransfer-
ase (e.g., Bertolino et al. 2006), suggest that individual differ-
ences in DA transmission are likely to play a critical role in the
young and in aging.
In the fMRI data, but not the behavioral data, group
differences rather than commonalities predominated: within
the ROIs, the main effect of the drugs on memory was
accompanied by age-related differences in their effects on
neural activity. Thus, the relationship between drug effects on
brain activity and behavior appears to differ qualitatively in the
2 age groups. The memory improvement may have reﬂected
a separate age-invariant drug effect, linked for example to an
increase in activity in unexamined regions. Alternatively, the
apparently opposite neural effects in the 2 groups may both
have been associated with an increase in overall encoding
efﬁcacy. Bromocriptine tended to enhance the group differ-
ences on Placebo, inducing tighter coupling between regional
activity and SM in both age groups (SM and forgetting effects).
Potentially, an interaction of drug with age group could reﬂect
a modulation of the strength of this coupling, as opposed to its
direction. However, it seems implausible that encoding efﬁcacy,
and thus the effect on performance, would not depend on the
direction of coupling. This would also be at odds with reversal of
group differences in the direction of this coupling by Sulpiride in
RIFG. Most importantly, an age-invariant mechanism for the
principal fMRI and behavioral effects does not account for
the dependence of the former on individual differences within
the older group.
As the foregoing caveats suggest, the absence of clear cut
behavioral effects of the drugs renders their neural effects more
complex to interpret. However, these neural effects are
themselves no less interpretable than behavioral effects, and
indeed some potential confounds between brain activity and
performance are avoided (Honey and Bullmore 2004; Wilkinson
and Halligan 2004). Put more simply and generally, there are not
prima facie reasons why an observed effect on one outcome
variable (brain imaging) is less interpretable when there is no
measurable effect on another outcome variable. Indeed, the
existence of brain changes in the face of apparently unchanged
behavioral observations is the basis for the notions of the value of
endophenotypes. Of course, in order to account for age-related
cognitive decline, age-related differences in brain activity must
ultimately be connected to age-related changes in performance.
The present link between the effects of the drugs on SM effects
and individual differences in memory within the old group is
critical in this regard and allows us to interpret the drug effects
as a correlate of age-related memory decline.
DA, Aging, and Neural Efﬁciency
As already noted, the ﬁndings are consistent with some of our
predictions but not others. Within RIFG, Sulpiride appeared to
de-couple activity from later memory performance so that
patterns of SM-related activity in the young resembled those in
the old at baseline in RIFG and in LIFG. However, Sulpiride did
not have parallel effects in LIFG, and thus did not consistently
render activity in the young more like that in the old.
Bromocriptine, conversely, was expected to render activity in
the old more like that in the young, and we did not ﬁnd
evidence of this. If anything, it tended to enhance rather than
attenuate the average group differences in neural activity. The
implications of this for the notion of age-related neural
inefﬁciency linked to DA depletion are mixed. The baseline
group differences we observe appear to reﬂect MTL activity
that gives rise to ineffective rather than effective encoding in
the old (see Drug effects in medial temporal lobes). Impor-
tantly, this coupling between activity and ineffective memory
encoding in the old was enhanced by D2 stimulation. This does
not ﬁt the prediction of an amelioration of age-related
processing and neural impairment with dopaminergic stimula-
tion. A possible mechanism for the Bromocriptine effects we
Cerebral Cortex March 2010, V 20 N 3 753observe is an increased (relative) sensitivity to D2 presynaptic
effects in aging, perhaps linked to postsynaptic receptor
downregulation (see Drug effects on brain and behavior). Thus
the present results present a more complex picture of
dopamine aging than a simple reduction in neural efﬁciency.
They do, however, do support the prediction of the dopamine
aging hypothesis that the greatest effects of DA stimulation in
the older group would be in those with the poorest
memory—those with the greatest potential degree of un-
derlying dopaminergic decline. This is considered further in
the next section.
Individual Differences in Drug Effects
The fMRI ﬁndings indicate that dopamine perturbation alters
the efﬁcacy with which neural activity supports later re-
membering. Importantly, the age-related differences in the
effects of this perturbation interacted with individual differ-
ences. Within the older group only, individual vulnerability to
drug effects varied according to the level of memory
performance: dopaminergic modulation of SM effects was most
pronounced in those with the poorest memory. Individual
differences in the neural substrates of episodic memory in
older adults were unmasked by D2 receptor stimulation, which
accentuated the differences in neural activity between the
young, and the old poorer performers. Thus, critically, age-
related variance in memory performance accounted for
variance in speciﬁc encoding-related activity in key regions.
This suggests that changes in DA systems with normal aging
contribute to, or are a marker of, age-related memory decline.
Conclusions
Our ﬁndings indicate an association between the well-
documented age-related decline in dopaminergic neurotrans-
mission, and the decline in episodic memory. This goes beyond
the established ‘‘correlative triad’’ between age, DA, and
cognition (Backman et al. 2006) in 2 ways. First, it shows that
in adults of different ages, DA perturbation differentially affects
the brain activity that predicts whether information will later
be remembered or forgotten. Second, it identiﬁes a link
between dopamine, memory networks, and performance
variability amongst older adults. Similar effects across a network
of medial temporal and frontostriatal regions are consistent
with several possible underlying mechanisms. A speculative
conclusion, and a hypothesis to be tested in future studies, is
that changes in DA signaling mediate an impairment of distinct
memory trace formation in the aging hippocampus. It will be
critical to establish the extent to which these age-related
neuromodulatory changes impact on other cognitive pro-
cesses, and the extent to which they are speciﬁc to dopamine
systems. On the basis of the present data, however, it is clear
that age-related changes in dopaminergic neuromodulation are
important and relevant to memory function.
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